앨라배마의 자궁내막암 임상 시험
자궁내막암 관련 연구 19개가 앨라배마 내 여러 지역에서 참여자를 모집하고 있습니다.
앨라배마의 도시
공식 연구 텍스트(영어)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- University of Alabama at Birmingham Cancer Center, Birmingham
피험자 모집 중2상
18세 이상 · 여성 · 2026. 11. 12. 업데이트됨 · NCT05112601Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
피험자 모집 중2상
전 연령 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT05564377A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- University of South Alabama, Mitchell Cancer Institute ( Site 6033), Mobile
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 10. 업데이트됨 · NCT06952504Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 6. 업데이트됨 · NCT07198074A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06760819Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- USAH Mitchell Cancer Inst, Mobile
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 3. 업데이트됨 · NCT07166094A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
- GSK Investigational Site, Birmingham
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 3. 업데이트됨 · NCT07286331A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 22. 업데이트됨 · NCT04657068Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT06293898177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT07189871Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- University of Alabama_6th Ave, Birmingham
피험자 모집 중1/2상
18세 이상 · 여성 · 2026. 9. 25. 업데이트됨 · NCT03564340DESTINY-PANTUMOUR04
- Research Site, Birmingham
피험자 모집 중관찰 연구
18세 ~ 130세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07124000ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Alabama at Birmingham, Birmingham
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT05059444Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
피험자 모집 중1/2상
12 Months – 30 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04851119The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
- University of Alabama at Birmingham, Birmingham
피험자 모집 중관찰 연구건강한 지원자 환영
18세 ~ 99세 · 여성 · 2026. 7. 29. 업데이트됨 · NCT03538665A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- 외 1개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 22. 업데이트됨 · NCT05208762Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 004, Birmingham
피험자 모집 중2상
18세 이상 · 여성 · 2026. 7. 16. 업데이트됨 · NCT06906341Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
피험자 모집 중1/2상
18세 이상 · 여성 · 2026. 4. 15. 업데이트됨 · NCT05559879SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.